Condensed Consolidated Statements of Cash Flows (Unaudited) $ in Thousands	9 Months Ended
	Sep. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)
Operating activities:
Net income (loss)	$ 21,495	$ (51,196)
Depreciation	465	325
Accretion of debt discount and loan costs	1,941	297
Amortization of intangible assets	4,103	728
Derivative liability		100
Stock-based compensation expense	10,223	11,600
Deferred income taxes	(15,972)
Bargain purchase gain	(27,336)
Changes in assets and liabilities:
Accounts receivable	(7,222)	(601)
Inventories, net of effect of acquisition	2,314	(1,460)
Prepaid expenses and other assets	1,826	(537)
Accounts payable and accrued expenses, net of effect of acquisition	8,998	(662)
Deferred revenue	(21,716)	47
Net cash flows from operating activities	(20,881)	(41,359)
Investing activities:
BELBUCA® acquisition	(3,902)
Purchase of equipment	(5)	(316)
Net cash flows from investing activities	(3,907)	(316)
Financing activities:
Proceeds from notes payable	45,000
Payment of notes payable	(30,000)
Payment of deferred financing fees	(2,798)
Equity financing costs		40
Proceeds from exercise of stock options	313	297
Proceeds from issuance of common stock		2,460
Net cash flows from financing activities	12,515	2,797
Net change in cash and cash equivalents	(12,273)	(38,878)
Cash and cash equivalents at beginning of year	32,019	83,560
Cash and cash equivalents at end of period	19,746	44,682
Cash paid for interest	3,816	$ 2,045
Non-cash Operating, Financing and Investing Activities:
Fair value of bargain purchase price of BELBUCA acquisition	27,300
Fair value of warrants, in connection with CRG term loan	$ 4,500